328 related articles for article (PubMed ID: 22983922)
41. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
42. ROCK2/ras
Masre SF; Rath N; Olson MF; Greenhalgh DA
Oncogene; 2017 May; 36(18):2529-2542. PubMed ID: 27991921
[TBL] [Abstract][Full Text] [Related]
43. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
[TBL] [Abstract][Full Text] [Related]
44. Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis.
Semenova G; Stepanova DS; Dubyk C; Handorf E; Deyev SM; Lazar AJ; Chernoff J
Oncogene; 2017 Sep; 36(38):5421-5431. PubMed ID: 28534510
[TBL] [Abstract][Full Text] [Related]
45. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
[TBL] [Abstract][Full Text] [Related]
46. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
47. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
48. Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells.
Prudnikova TY; Villamar-Cruz O; Rawat SJ; Cai KQ; Chernoff J
Oncogene; 2016 Apr; 35(17):2178-85. PubMed ID: 26257058
[TBL] [Abstract][Full Text] [Related]
49. PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling.
Shrestha Y; Schafer EJ; Boehm JS; Thomas SR; He F; Du J; Wang S; Barretina J; Weir BA; Zhao JJ; Polyak K; Golub TR; Beroukhim R; Hahn WC
Oncogene; 2012 Jul; 31(29):3397-408. PubMed ID: 22105362
[TBL] [Abstract][Full Text] [Related]
50. p-21-Activated kinase 1 mediates gastrin-stimulated proliferation in the colorectal mucosa via multiple signaling pathways.
Huynh N; Yim M; Chernoff J; Shulkes A; Baldwin GS; He H
Am J Physiol Gastrointest Liver Physiol; 2013 Mar; 304(6):G561-7. PubMed ID: 23306081
[TBL] [Abstract][Full Text] [Related]
51. Resistance to MEK inhibitors: should we co-target upstream?
Poulikakos PI; Solit DB
Sci Signal; 2011 Mar; 4(166):pe16. PubMed ID: 21447797
[TBL] [Abstract][Full Text] [Related]
52. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
53. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
54. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
55. Characterization of KRAS rearrangements in metastatic prostate cancer.
Wang XS; Shankar S; Dhanasekaran SM; Ateeq B; Sasaki AT; Jing X; Robinson D; Cao Q; Prensner JR; Yocum AK; Wang R; Fries DF; Han B; Asangani IA; Cao X; Li Y; Omenn GS; Pflueger D; Gopalan A; Reuter VE; Kahoud ER; Cantley LC; Rubin MA; Palanisamy N; Varambally S; Chinnaiyan AM
Cancer Discov; 2011 Jun; 1(1):35-43. PubMed ID: 22140652
[TBL] [Abstract][Full Text] [Related]
56. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
57. Epithelial stem cell mutations that promote squamous cell carcinoma metastasis.
White RA; Neiman JM; Reddi A; Han G; Birlea S; Mitra D; Dionne L; Fernandez P; Murao K; Bian L; Keysar SB; Goldstein NB; Song N; Bornstein S; Han Z; Lu X; Wisell J; Li F; Song J; Lu SL; Jimeno A; Roop DR; Wang XJ
J Clin Invest; 2013 Oct; 123(10):4390-404. PubMed ID: 23999427
[TBL] [Abstract][Full Text] [Related]
58. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia.
Case M; Matheson E; Minto L; Hassan R; Harrison CJ; Bown N; Bailey S; Vormoor J; Hall AG; Irving JA
Cancer Res; 2008 Aug; 68(16):6803-9. PubMed ID: 18701506
[TBL] [Abstract][Full Text] [Related]
59. The progression in the mouse skin carcinogenesis model correlates with ERK1/2 signaling.
Katsanakis KD; Gorgoulis V; Papavassiliou AG; Zoumpourlis VK
Mol Med; 2002 Oct; 8(10):624-37. PubMed ID: 12477973
[TBL] [Abstract][Full Text] [Related]
60. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.
Chappell WH; Steelman LS; Long JM; Kempf RC; Abrams SL; Franklin RA; Bäsecke J; Stivala F; Donia M; Fagone P; Malaponte G; Mazzarino MC; Nicoletti F; Libra M; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Laidler P; Milella M; Tafuri A; Bonati A; Evangelisti C; Cocco L; Martelli AM; McCubrey JA
Oncotarget; 2011 Mar; 2(3):135-64. PubMed ID: 21411864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
